Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

ClinicalTrials.gov ID: NCT00094055

Public ClinicalTrials.gov record NCT00094055. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131 I Treatment

Study identification

NCT ID
NCT00094055
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
60 participants

Conditions and interventions

Interventions

  • AG013736 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2004
Primary completion
Dec 31, 2008
Completion
Dec 31, 2008
Last update posted
Jun 25, 2012

2004 – 2009

United States locations

U.S. sites
9
U.S. states
7
U.S. cities
8
Facility City State ZIP Site status
Pfizer Investigational Site Santa Monica California 90404
Pfizer Investigational Site Aurora Colorado 80010
Pfizer Investigational Site Denver Colorado 80220
Pfizer Investigational Site Chicago Illinois 60637
Pfizer Investigational Site Baltimore Maryland 21231-1000
Pfizer Investigational Site Baltimore Maryland 51231
Pfizer Investigational Site Ann Arbor Michigan 48109
Pfizer Investigational Site Philadelphia Pennsylvania 19111
Pfizer Investigational Site Houston Texas 77030-4009

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00094055, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 25, 2012 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00094055 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →